XSpray Microparticles AB announced a partnership with Cerbios-Pharma SA of Lugano, Switzerland for the joint development of HPAI (high potency active ingredients). HPAI development will be provided by XSpray in Stockholm, while the cGMP production for clinical and commercial use will be carried out at Cerbios in Lugano.
“We are very pleased with this partnership. We believe that RightSize technology offers significant advantages in the development of HPAIs”, commented XSpray’s CEO, Dr. Per Andersson. “This partnership is an important step towards the development of HPAIs with unique characteristics.”
The formulation and manufacturing abilities of XSpray’s RightSize technology offer the opportunity to improve drug substances through various strategies, enabling full control over particle design and production – simplifying drug formulation, extending delivery options and allowing the addition of innovative properties that truly benefit patients.
RightSize technology not only provides a superior process to traditional methods. It can also be effectively scaled from discovery scale up to production volumes, making it an important breakthrough in the manufacture of pharmaceutical particles using supercritical fluid technology.
One of the advantages of this technology is that the moderate temperatures used make it ideal for particle size reduction of thermolabile compounds.
“We are enthusiastic about this partnership with XSpray. Access to RightSize technology will strengthen our API development and manufacturing for third parties”, says Dr. Gabriel Haering, CEO of Cerbios. “Through the use of this innovative technology for HPAIs, Cerbios will be able to offer a unique capability, enabling the generation not only of particles having narrow particle size distribution but also different crystal forms and/or polymorphs up to the full control of particle design, including solid state form. In combination with other technologies available at Cerbios it will generate intellectual property that will definitely help our partners in their success.”
Financial terms for access to XSpray’s RightSize technology and expertise will not be disclosed.
Date: September 4, 2012
Source: Associated Press
Filed Under: Drug Discovery